rss
Ann Rheum Dis 1997;56:97-102 doi:10.1136/ard.56.2.97
  • Extended reports

Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate

  1. Christophe Bolognaa,
  2. Marie-Christinne Picotb,
  3. Christian Jorgensena,
  4. Philippe Viua,
  5. Regis Verdierb,
  6. Jacques Sanya
  1. aCHU Lapeyronie, Montpellier, France: Service d’Immuno-Rhumatologie, Fédération de Rhumatologie , bDépartement d’Information Médicale
  1. Professeur Jacques Sany, Service d’Immuno-Rhumatologie, CHU Lapeyronie, 34295 Montpellier Cedex 5, France.
  • Accepted 24 October 1996

Abstract

OBJECTIVE To report cancer cases in 426 rheumatoid arthritis patients treated with methotrexate, and determine whether there was an increased incidence of cancer compared with patients never treated with methotrexate (rheumatoid controls) and to the whole regional population.

METHODS The duration of methotrexate treatment was 37.4 (SD 27.9) months. This population was compared with 420 rheumatoid arthritis controls and with a regional population of 812 344 people. Life table analysis was performed to compare the cancer incidence in the two rheumatoid populations. Adjustment for potentially confounding factors was done. The indirect standardisation method was used to compare each rheumatoid population with the regional population.

RESULTS Eight cases of cancer (1.88%; 4.04 cases/1000 person years) were diagnosed in the methotrexate population v six (1.43%; 58.8 cases/1000 person years) in the rheumatoid controls. The life table method showed a higher incidence of cancer in the rheumatoid controls (P = 0.0001). In a multivariate analysis (Cox model), the only significant factor explaining this difference in the cancer incidence was age (P = 0.02). In the regional population there were 6418 new cases of cancer (0.79%; 2.85 cases/1000 person years). By the indirect standardisation method, the ratio of observed cases to expected cases of cancer in each of the rheumatoid populations was not significantly different from 1.

CONCLUSIONS In these eight cases, methotrexate was not found to be responsible for generating cancers. However, because of data regarding lymphomas and methotrexate, and because of the short follow up, especially in the control group, longer prospective studies are warranted.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.